IRIS Archives

Information and Referral and Internet Sightings

IRIS@LISTSERV.ICORS.ORG
Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
Antidepressant GLYX-13
From:
Sylvia Caras <[log in to unmask]>
Reply To:
[log in to unmask]
Date:
Thu, 2 Sep 2010 10:38:42 -0700
Content-Type:
text/plain
Parts/Attachments:
text/plain (16 lines) 
Naurex's Novel Antidepressant GLYX-13 Recognized as One of 
Windhover's Top 10 Neuroscience Projects to Watch

 From the PharmaLive.com News Archive - Aug. 31, 2010

Naurex today reported that its clinical stage candidate for the 
treatment of depression, GLYX-13, and its second-generation NRX-1050 
series have been selected for inclusion on Windhover's list of the 
"Top 10 Most Interesting Neuroscience Projects to Watch." They were 
chosen by a committee that included Windhover Information, the 
publishers of IN VIVO and Start-Up, and independent CNS expert Harry 
Tracy, president of NI Research and editor of the neuroscience 
business analysis journal NeuroInvestment.

www.peoplewho.org

ATOM RSS1 RSS2